Importantly, TxflSig1 predicted NSCLC response to anti-PD1 therapy at an AUC of 0.8, which was the best among all well-established ICB biomarkers, including CD274, IFNG, and Merck18 (T-cell-inflamed signature) [51] (Figure 3B). Here, IFNG is linked to non-small cell lung carcinoma.